Introduction
============

Cancer is a major serious challenge to human health worldwide. According to the latest report from American Cancer Society, 1,688,780 new cancer cases and 600,920 cancer deaths are expected to occur in the United States in 2017.[@b1-ott-10-5263] Cancer is considered as a multi-genetic disease caused by substantial accumulation of DNA mutations.[@b2-ott-10-5263] Genetic variations will induce the activation of oncogenes and inactivation of tumor suppressor genes, subsequently resulting in unrestrained cell proliferation and neoplasm formation.[@b3-ott-10-5263],[@b4-ott-10-5263] With cancer genome sequencing widely applied, identifying the mutations in an individual patient may contribute to preventing cancer efficiently.[@b5-ott-10-5263]

MicroRNA (miRNA), a type of noncoding RNA containing approximately 22 nucleotides, participates in regulating gene expression at the post-transcriptional level.[@b6-ott-10-5263] miRNA biogenesis is a sophisticated process involving several steps. To be specific, miRNA is initially transcribed into a 300- to 1,000-nucleotide-length pri-miRNA,[@b7-ott-10-5263] and then the pri-miRNA is processed into two-nucleotide strands precursor-miRNA (pre-miRNA) in the nucleus in collaboration with a nuclear protein known as DiGeorge Syndrome Critical Region 8 (DGCR8).[@b8-ott-10-5263] Finally, the pre-miRNA is further cut by the RNase III enzyme Dicer in the cytoplasm to generate a mature miRNA.[@b9-ott-10-5263] Gem-associated protein 4 (GEMIN4), encoded by *GEMIN4* gene, along with the mature miRNA, Argonaute (Ago) protein and gem-associated protein 3 (GEMIN3) participates in the formation of the miRNA-induced silencing complex (RISC), which promotes the mature miRNAs to bind to their target mRNAs and then regulates the expression of target genes.[@b10-ott-10-5263],[@b11-ott-10-5263]

Recent studies have found that miRNAs are generally dysregulated in cancer and function as oncogenes or tumor suppressor genes.[@b12-ott-10-5263],[@b13-ott-10-5263] Furthermore, the alteration in miRNA biogenesis genes may be associated with susceptibility to cancer probably by influencing the function of miRNAs.[@b14-ott-10-5263] Furthermore, a body of evidence has indicated that some single-nucleotide polymorphisms (SNPs) in the *GEMIN4* gene, a major miRNA biogenesis gene, are associated with the risk of several types of cancer,[@b15-ott-10-5263]--[@b19-ott-10-5263] but the published results are inconsistent.[@b15-ott-10-5263]--[@b17-ott-10-5263] Therefore, in the present study, we undertook a meta-analysis to analyze the association between three major SNPs in the *GEMIN4* gene (rs2740348, rs7813, and rs3744741) and the risk of cancer based on published articles.

Methods
=======

Literature search
-----------------

Relevant articles published prior to July 20, 2017 were mainly identified through searches of Web of Science, PubMed, Cochrane Library, Chinese Wan Fang, and Chinese National Knowledge Infrastructure databases online. The key terms of literature search included "genetic polymorphism," "single nucleotide polymorphism," "genetic variants," "nuclear organelle associated protein 4," "*GEMIN4*," "cancer," "carcinoma," "malignancy," and "tumor." Furthermore, manual retrieval was undertaken additionally by browsing the references from eligible articles. Each retrieved article including title, abstract, and full text was comprehensively evaluated by two independent authors to determine whether it could be included in the final analysis. If their opinions were not consistent, other authors critically assessed whether the retrieved article should be included.

Eligibility criteria
--------------------

The qualified articles should simultaneously meet three major inclusion criteria as follow: 1) concerning the association between the *GEMIN4* polymorphism and cancer; 2) case--control study; and 3) complete data concerning the frequencies of genotype or sufficient original data for calculating the frequencies of genotype. Retrieved articles were excluded if they met one of the two major exclusion criteria as follows: 1) duplicated or retracted articles, 2) review, case report, letter, or short commentary. In addition, the healthy control should be free of any type of cancer.

Data extraction
---------------

Information about the eligible article including the author's name, publication date, characteristics of case and control, methods of genotyping, *P*-value of the Hardy--Weinberg equilibrium (HWE) test, sample size of the study, and number of genotype was extracted from full text by two independent authors separately. The Newcastle--Ottawa Scale (NOS) was used to evaluate the quality of included studies as described previously.[@b20-ott-10-5263]

Statistical analysis
--------------------

Firstly, the distribution of genotype in the control was evaluated to ascertain whether it conformed to the HWE through the chi-square goodness-of-fit test. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to estimate the association between the *GEMIN4* polymorphism and risk of cancer. Cochran's Q statistic in combination with the I-squared (*I*^2^) metric was used to assess heterogeneity. Specifically, *P*\<0.10 or *I*^2^\>50% was considered as indicative of significant heterogeneity. The random-effects model was used to estimate the pooled OR with significant heterogeneity existing; otherwise, the fixed-effects model was developed. The best-fitting genetic model was chosen to estimate the association between the *GEMIN4* polymorphism and the risk of cancer, according to previously published articles.[@b21-ott-10-5263] Subgroup analysis was further undertaken based on ethnicity. Publication bias was evaluated through funnel plots in combination with Egger's linear regression test. Publication bias was considered significant when the *P*-value of Egger's test was less than 0.05. Sensitivity analysis was conducted to evaluate the stability of pooled results through omitting a single study each time to examine its influence on the total OR value. Statistical data analyses were conducted by using STATA 11.0 (STATA Corp., College Station, TX, USA).

Results
=======

Characteristics of the included studies
---------------------------------------

In general, 70 relevant articles were originally chosen from different electronic databases. According to the inclusion and exclusion criteria, 55 articles were eliminated and 15 qualified articles (9 articles referring to rs2740348,[@b15-ott-10-5263],[@b18-ott-10-5263],[@b22-ott-10-5263],[@b28-ott-10-5263] 11 articles referring to rs7813,[@b15-ott-10-5263]--[@b17-ott-10-5263],[@b19-ott-10-5263],[@b22-ott-10-5263]--[@b25-ott-10-5263],[@b29-ott-10-5263]--[@b31-ott-10-5263] and 5 articles referring to rs3744741[@b15-ott-10-5263],[@b16-ott-10-5263],[@b22-ott-10-5263]--[@b24-ott-10-5263]) were finally included in the meta-analysis ([Figure 1](#f1-ott-10-5263){ref-type="fig"}). Specifically, details of the eliminated articles are shown in [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=147204.pdf).

The main characteristics of all qualified studies are listed in [Tables 1](#t1-ott-10-5263){ref-type="table"}[](#t2-ott-10-5263){ref-type="table"}--[3](#t3-ott-10-5263){ref-type="table"}, respectively. Each included study got no less than 7 points referring to the NOS score, and the genotype distribution in the control conformed to HWE.

Quantitative data synthesis
---------------------------

For rs2740348, the pooled result with 3,604 cases and 3,770 controls showed that it was significantly associated with increased risk of cancer in the recessive model (GG vs GC/CC: OR =1.16, 95% CI =1.05--1.29, *P*=0.004; [Figure 2A](#f2-ott-10-5263){ref-type="fig"}). The result of subgroup analysis by ethnicity showed that rs2740348 was significantly associated with increased risk of cancer in a mixed population (GG vs GC/CC: OR =1.23, 95% CI =1.05--1.43, *P*=0.009; [Figure 2A](#f2-ott-10-5263){ref-type="fig"}), but not in Caucasians (GG vs GC/CC: OR =1.20, 95% CI =0.95--1.52, *P*=0.127; [Figure 2A](#f2-ott-10-5263){ref-type="fig"}) and Asians (GG vs GC/CC: OR =1.07, 95% CI =0.90--1.27, *P*=0.423; [Figure 2A](#f2-ott-10-5263){ref-type="fig"}).

For rs7813, the pooled result with 4,729 cases and 4,562 controls also indicated that rs7813 was related to increased risk of cancer in the recessive model (TT vs TC/CC: OR =1.12, 95% CI =1.03--1.22, *P*=0.009; [Figure 2B](#f2-ott-10-5263){ref-type="fig"}). Subgroup analysis by ethnicity further indicated that rs7813 significantly increased susceptibility to cancer in Asians (TT vs TC/CC: OR =1.14, 95% CI =1.02--1.27, *P*=0.019; [Figure 2B](#f2-ott-10-5263){ref-type="fig"}) rather than Caucasians (TT vs TC/CC: OR =1.09, 95% CI =0.95--1.25, *P*=0.206; [Figure 2B](#f2-ott-10-5263){ref-type="fig"}).

As for rs3744741, the pooled result with 2,167 cases and 2,143 controls suggested no association existed between rs3744741 and the risk of cancer in the recessive model (CC vs CT/TT: OR =1.04, 95% CI =0.92--1.18, *P*=0.509; [Figure 2C](#f2-ott-10-5263){ref-type="fig"}). Furthermore, no association was found in other genetic models ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=147204.pdf)).

Sensitivity analysis and publication bias
-----------------------------------------

To evaluate the stability of the pooled results, sensitivity analysis was conducted. The result of sensitivity analysis showed the pooled OR value did not significantly change when omitting any single study ([Figure 3](#f3-ott-10-5263){ref-type="fig"}). To evaluate the publication bias, the funnel plot and Egger's linear regression test were applied. Funnel plots of rs2740348, rs7813, and rs3744741 were visually symmetrical ([Figure 4](#f4-ott-10-5263){ref-type="fig"}) and, furthermore, the result of Egger's test showed no evidence of publication bias (*P*=0.769, 95% CI: −2.90, 2.24 for rs2740348, *P*=0.751, 95% CI: −3.61, 4.83 for rs7813, *P*=0.557, 95% CI: −4.03, 6.14 for rs3744741, respectively).

Discussion
==========

*GEMIN4* gene is located on the human chr17. Genetic variants in the *GEMIN4* gene might lead to a decreased inhibitory effect on the proliferation of hepatocarcinoma cells and simultaneously have an impact on the DNA repair system by altering the expression of proliferation-associated genes and DNA repair genes.[@b32-ott-10-5263] Several studies have found that genetic variants in the *GEMIN4* gene not only alter the susceptibility to cancer,[@b15-ott-10-5263]--[@b19-ott-10-5263] but also influence the survival time of patients with cancer.[@b33-ott-10-5263],[@b34-ott-10-5263] However, as far as we know, most of these studies are small-scale case--control studies. Although a meta-analysis conducted by Zhu et al firstly showed that rs2740348 and rs7813 polymorphisms were associated with increased risk of cancer, the total number of subjects in their meta-analysis was also limited.[@b35-ott-10-5263] Compared with previous meta-analysis, one advantage of our meta-analysis is that it included larger sample size, nearly double that of studies earlier. In addition, another new finding of our study is that it firstly evaluates the association between the rs3744741 polymorphism and the risk of cancer.

The rs2740348 polymorphism is a C/G mutation located in the exon region of the *GEMIN4* gene. Liu et al found that rs2740348 was associated with decreased risk of prostate cancer.[@b15-ott-10-5263] A similar protective effect was also shown in colon cancer.[@b18-ott-10-5263] However, Zhao et al suggested no association existed in colorectal cancer.[@b28-ott-10-5263] Moreover, there was no association with lung cancer,[@b24-ott-10-5263] chronic myeloid leukemia, and gastric cancer.[@b26-ott-10-5263],[@b27-ott-10-5263] More interestingly, Yang et al found that a haplotype of the *GEMIN4* gene including rs2740348 was associated with increased risk of bladder cancer.[@b31-ott-10-5263] In our present meta-analysis, we found that rs2740348 was significantly associated with increased risk of cancer in the general population under the recessive model (GG vs GC/CC), which agreed with the result reported by Zhu et al.[@b35-ott-10-5263] However, this conclusion was only confirmed in a mixed population, but not in Asians and Caucasians. Therefore, the discrepancy of the results might be partly attributed to the difference of the study population.

The rs7813 polymorphism is a C/T mutation located in the exon region of the *GEMIN4* gene. Liu et al found that rs7813 was associated with an increased risk of prostate cancer,[@b15-ott-10-5263] and Nikolić et al also found a significant association between rs7813 and the risk of prostate cancer progression.[@b19-ott-10-5263] However, Fang et al found that rs7813 was associated with decreased risk of lung cancer.[@b17-ott-10-5263] A similar protective effect was found in ovarian and breast cancers.[@b30-ott-10-5263],[@b34-ott-10-5263] In addition, some studies did not report any significant association between rs7813 and the risk of breast cancer,[@b23-ott-10-5263] lung cancer, and esophageal squamous cell carcinoma.[@b24-ott-10-5263],[@b32-ott-10-5263] In the present study, we reported that rs7813 was related to an increased risk of cancer in the general population under the recessive model (TT vs TC/CC), but this conclusion was only confirmed in Asians, not in Caucasians, which is contrary to a previous meta-analysis.[@b35-ott-10-5263] Thus, we inferred that the discrepancy might be explained by the diversity of study population and tumor types.

The rs3744741 polymorphism is a C/T mutation located in the exon region of the *GEMIN4* gene. Liu et al found that the T allele of rs3744741 was associated with decreased risk of III/IV stage of prostate cancer,[@b15-ott-10-5263] but no significant association between rs7813 and the risk of cancer was reported in breast and lung cancers.[@b23-ott-10-5263],[@b24-ott-10-5263] Moreover, we did not find any significant associations between rs7813 and the risk of cancer, neither in Asians nor in Caucasians under overall genetic models. Considering that the sample size was relatively small (2,167 cases and 2,143 controls), this conclusion should be further validated by some more large-scale studies.

Certainly, several limitations still existed in our meta-analysis. Firstly, the sample size of our meta-analysis, especially for rs3744741, was still relatively small. The conclusion should be reconfirmed by more large-scale studies. Secondly, the characteristics of included studies, such as age and gender, were diverse and might affect the results of meta-analysis. Due to a lack of valid data pertaining to age and gender for all included studies, we could not evaluate their impacts on the pooled OR value. Finally, our study only evaluated the impact of these three SNPs on the risk of cancer separately and ignored the interaction effects of multiple SNPs, which was a deficit we must acknowledge.

Conclusion
==========

Our study has demonstrated that rs2740348 and rs7813 polymorphism in *GEMIN4* gene are risk factors for cancer, but rs3744741 polymorphism is not associated with the risk of cancer. These findings should be further reconfirmed by more large-scale studies.
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![Quantitative analysis for the association between *GEMIN4* gene polymorphism and the risk of cancer.\
**Notes:** (**A**) Forest plot of rs2740348 polymorphism and the risk of cancer under the recessive model (GG vs GC/CC). (**B**) Forest plot of rs7813 polymorphism and the risk of cancer under the recessive model (TT vs TC/CC). (**C**) Forest plot of rs3744741 polymorphism and the risk of cancer under the recessive model (CC vs CT/TT).](ott-10-5263Fig2){#f2-ott-10-5263}

![Sensitivity analysis for the association of *GEMIN4* gene polymorphism with the risk of cancer.\
**Notes:** (**A**) Sensitivity analysis for rs2740348 polymorphism and the risk of cancer under the recessive model (GG vs GC/CC). (**B**) Sensitivity analysis for rs7813 polymorphism and the risk of cancer under the recessive model (TT vs TC/CC). (**C**) Sensitivity analysis for rs3744741 polymorphism and the risk of cancer under the recessive model (CC vs CT/TT).](ott-10-5263Fig3){#f3-ott-10-5263}

![Funnel plot of *GEMIN4* gene polymorphism and the risk of cancer.\
**Notes:** (**A**) Funnel plot of rs2740348 polymorphism and the risk of cancer under the recessive model (GG vs GC/CC). (**B**) Funnel plot of rs7813 polymorphism and the risk of cancer under the recessive model (TT vs TC/CC). (**C**) Funnel plot of rs3744741 polymorphism and the risk of cancer under the recessive model (CC vs CT/TT).](ott-10-5263Fig4){#f4-ott-10-5263}

###### 

Main characteristics of studies included in the meta-analysis for rs2740348

  Studies                                      Country   Ethnicity   Age, year (case/control)   Male, % (case/control)   Cancer type                Genotype method      NOS score   HWE test (control)   Simple size (case/control)   Genotype (case/control)   
  -------------------------------------------- --------- ----------- -------------------------- ------------------------ -------------------------- -------------------- ----------- -------------------- ---------------------------- ------------------------- ---------
  Ye et al[@b22-ott-10-5263]                   USA       Caucasian   63.3±11.0/63.2±10.63       88.4/88.4                Esophageal cancer          SNPlex assay         8           Yes                  346/346                      238/238                   108/108
  Jiang et al[@b23-ott-10-5263]                China     Asian       NA                         0/0                      Breast cancer              TaqMan assay         8           Yes                  863/888                      665/682                   198/206
  Liu et al[@b15-ott-10-5263]                  China     Asian       71.43±9.38/71.15±9.64      100/100                  Prostate cancer            HRM method           8           Yes                  300/244                      246/182                   54/62
  Kim et al[@b24-ott-10-5263]                  Korea     Asian       61.5±10.9/61.5±11.3        80/80                    Lung cancer                Spectrometry-based   8           Yes                  92/90                        74/71                     18/19
  Gutiérrez-Malacatt et al[@b26-ott-10-5263]   Mexico    Mixed       40.52±8.46/44.87±14.88     56/56                    Chronic myeloid leukemia   TaqMan assay         7           Yes                  312/469                      203/291                   109/178
  Horikawa et al[@b25-ott-10-5263]             USA       Caucasian   60.29±10.57/60.46±10.88    67/67                    Renal cell carcinoma       SNPlex assay         8           Yes                  276/278                      192/168                   84/110
  Xie et al[@b27-ott-10-5263]                  China     Asian       NA                         72.3/72.5                Gastric cancer             PCR-LDR              7           Yes                  137/140                      110/115                   27/25
  Zhao et al[@b28-ott-10-5263]                 China     Asian       NA                         57.1/65.5                Colon cancer               PCR-LDR              7           Yes                  163/142                      128/114                   35/28
  Mullany et al[@b18-ott-10-5263]              USA       Mixed       NA                         NA                       Colon cancer               PCR-RFLP             8           Yes                  1,115/1,173                  798/782                   317/391

**Note:** Data presented as mean ± standard deviation.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; NA, not available; NOS, Newcastle--Ottawa Scale.

###### 

Main characteristics of studies included in the meta-analysis for rs7813

  Studies                            Country   Ethnicity   Age, year (case/control)   Male, % (case/control)   Cancer type                          Genotype method      NOS score   HWE test (control)   Simple size (case/control)   Genotype (case/control)   
  ---------------------------------- --------- ----------- -------------------------- ------------------------ ------------------------------------ -------------------- ----------- -------------------- ---------------------------- ------------------------- ---------
  Ye et al[@b22-ott-10-5263]         USA       Caucasian   63.3±11.0/63.2±10.63       88.4/88.4                Esophageal cancer                    SNPlex assay         8           Yes                  346/346                      112/105                   234/241
  Jiang et al[@b23-ott-10-5263]      China     Asian       NA                         0/0                      Breast cancer                        TaqMan assay         8           Yes                  866/885                      397/402                   469/483
  Liu et al[@b15-ott-10-5263]        China     Asian       71.43±9.38/71.15±9.64      100/100                  Prostate cancer                      HRM method           8           Yes                  300/244                      192/144                   108/100
  Kim et al[@b24-ott-10-5263]        Korea     Asian       61.5±10.9/61.5±11.3        80/80                    Lung cancer                          Spectrometry-based   8           Yes                  98/99                        42/47                     56/52
  Sung et al[@b16-ott-10-5263]       Korea     Asian       46.5±10.9/46.0±12.4        0/0                      Breast cancer                        TaqMan assay         8           Yes                  558/567                      236/218                   322/349
  Qu et al[@b29-ott-10-5263]         China     Asian       NA                         67.2/64.3                Esophageal squamous cell carcinoma   PCR-RFLP             8           Yes                  381/426                      163/186                   218/240
  Fang et al[@b17-ott-10-5263]       China     Asian       56.26±11.71/56.13±11.64    0/0                      Lung cancer                          TaqMan assay         8           Yes                  473/395                      242/153                   231/242
  Horikawa et al[@b25-ott-10-5263]   USA       Caucasian   60.29±10.57/60.46±10.88    67/67                    Renal cell carcinoma                 SNPlex assay         8           Yes                  277/278                      96/75                     181/203
  Nikolić et al[@b19-ott-10-5263]    Serbia    Caucasian   NA                         100/100                  Prostate cancer                      TaqMan assay         7           Yes                  355/319                      114/101                   241/218
  Liang et al[@b30-ott-10-5263]      USA       Caucasian   NA                         0/0                      Ovarian cancer                       Illumina             8           Yes                  339/267                      123/93                    216/174
  Yang et al[@b31-ott-10-5263]       USA       Caucasian   63.5±10.9/63.3±10.6        79/79                    Bladder cancer                       SNPlex assay         8           Yes                  736/736                      225/222                   511/514

**Note:** Data presented as mean ± standard deviation.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; NA, not available; NOS, Newcastle--Ottawa Scale.

###### 

Main characteristics of studies included in the meta-analysis for rs3744741

  Studies                         Country   Ethnicity   Age, year (case/control)   Male, % (case/control)   Cancer type         Genotype method      NOS score   HWE test (control)   Simple size (case/control)   Genotype (case/control)             
  ------------------------------- --------- ----------- -------------------------- ------------------------ ------------------- -------------------- ----------- -------------------- ---------------------------- ------------------------- --------- -------
  Ye et al[@b22-ott-10-5263]      USA       Caucasian   63.3±11.0/63.2±10.63       88.4/88.4                Esophageal cancer   SNPlex assay         8           Yes                  346/346                      268/250                   73/88     5/8
  Jiang et al[@b23-ott-10-5263]   China     Asian       NA                         0/0                      Breast cancer       TaqMan assay         8           Yes                  862/887                      440/466                   353/354   69/67
  Liu et al[@b15-ott-10-5263]     China     Asian       71.43±9.38/71.15±9.64      100/100                  Prostate cancer     HRM method           8           Yes                  300/244                      188/142                   92/82     20/20
  Kim et al[@b24-ott-10-5263]     Korea     Asian       61.5±10.9/61.5±11.3        80/80                    Lung cancer         Spectrometry-based   8           Yes                  100/99                       56/60                     38/34     6/5
  Sung et al[@b16-ott-10-5263]    Korea     Asian       46.5±10.9/46.0±12.4        0/0                      Breast cancer       TaqMan assay         8           Yes                  559/567                      331/327                   198/207   30/33

**Note:** Data presented as mean ± standard deviation.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; NA, not available; NOS, Newcastle--Ottawa Scale.
